UCERIS, developed by Salix Pharmaceuticals, is a rectally administered corticosteroid. The tentative FDA approval means the product meets quality, safety and efficacy standards, but awaits resolution of patient issues before receiving final approval.
More articles on gastroenterology:
19 things to know about GI compensation & satisfaction in 2014
How has the Obama presidency affected the field of GI?
Will CMS cover virtual colonoscopy?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.